Nebenwirkungen · Adtralza
Adtralza 150 mg solution for injection in pre-filled syringe Adtralza 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 7
HOS-145553 · Präparat HOS-099366
Anti-drug-antibody (ADA) responses were not associated with any impact on tralokinumab exposure, safety, or efficacy in patients receiving tralokinumab for up to 6 years (in phase 2/phase 3 atopic dermatitis studies followed by the long-term extension study ECZTEND). No immunogenicity-related adverse events such as immune-complex disease, serum sickness/serum sickness-like reactions, or anaphylaxis were observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-28T11:56:00Z · SHA-256 83eaa444d96a4d6e69d81213cba4604bd7b5b4375717ab35b9ffffc1dd714534 · Passage af0d8b9f69e393ae3a674d989c76b756e8a9a11010cc85028618fe243bc6d96a · Zeichen 4922–5338 im Abschnitt